Skip to main content

Currently Skimming:

CLINICAL TRIALS
Pages 14-15

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 14...
... Discussion Participants expressed the opinion that, with all the limitations and problems of passive surveillance and LLDBs, as discussed earlier, the premarketing period is the best time to obtain data on the safety of vaccines. However, premarketing studies conducted to support licensure often use sample sizes more appropriate for studying efficacy and commonly occurring adverse events and usually do not study samples large enough to detect rarely occurring adverse events.
From page 15...
... They responded that in general, prevention trials usually require much larger sample sizes and longer time periods for their completion than treatment trials and that the cost is correspondingly greater. In addition, it is difficult to get sufficient people to accept randomization in vaccine trials for a period sufficient to detect rare adverse events (this is discussed in a subsequent section)


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.